We are live on ! Find out more

Beta Bionics

BBNX

Market cap $1.04B

19.16 USD

-0.18

0.93%

At close Updated Oct 23, 4:00 PM EDT

1 day

-0.93%

5 days

15.42%

1 month

-13.65%

3 months

18.78%

6 months

67.63%

Year to date

-34.5%

1 year

-4.3%

5 years

-18.92%

10 years

-18.92%

About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Employees: 423

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 1.4%

Neutral 98%

Negative 0.6%

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , Oct. 23, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NasdaqGM: BBNX) of a class action securities lawsuit.

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

BBNX IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BBNX IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

Kaplan Fox Notifies Beta Bionics, Inc. (BBNX) Investors That Time Is Running Out to Lead the Securities Class Action - Deadline November 3, 2026

New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Notifies Beta Bionics, Inc. (BBNX) Investors That Time Is Running Out to Lead the Securities Class Action - Deadline November 3, 2026

BBNX Investor Alert: Beta Bionics, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Leading the Securities Class Action Lawsuit

San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump ("iLet").

BBNX Investor Alert: Beta Bionics, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Leading the Securities Class Action Lawsuit

BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA). Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now to Hagens Berman to discuss their legal options.

BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action

Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Act Ahead of the Lead Plaintiff Deadline on November 3, 2026

BBNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Beta Bionics between July 30, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

BBNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

BBNX Deadline News: Beta Bionics Investors are Notified of the Imminent November 3 Securities Fraud Class Action – Contact BFA Law if You Lost Money

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Beta Bionics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beta-bionics-class-action-lawsuit.

BBNX Deadline News: Beta Bionics Investors are Notified of the Imminent November 3 Securities Fraud Class Action – Contact BFA Law if You Lost Money

BBNX FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

New York, New York--(Newsfile Corp. - October 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. SO WHAT: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BBNX FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNX

BBNX 12-DAY DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

San Francisco, California--(Newsfile Corp. - October 22, 2026) - Hagens Berman reminds investors in Beta Bionics, Inc. (NASDAQ: BBNX) of the pending securities class action lawsuit and upcoming November 3, 2026 lead plaintiff deadline under the Private Securities Litigation Reform Act (PSLRA). Investors who suffered substantial losses purchasing Beta Bionics stock during the Class Period between July 30, 2025 and February 24, 2026, inclusive, are encouraged to submit your losses now to Hagens Berman to discuss their legal options.

BBNX 12-DAY DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

See News Rankings

Price charts implemented using Lightweight Charts™